However, the development of rhTSH and its approval in 2007 by the US Food and Drug Administration for the treatment of patients with DTC without evidence of metastatic disease has allowed the required TSH increase to be achieved without inducing hypothyroidism with thyroid hormone withdrawal, which is associated with a poor quality of life (15). Here, TG is linked to metastatic neoplasm.